A Phase 2 interventional study of Meloxicam 7.5 mg and Meloxicam 15 mg in Dysmenorrhea, sponsored by Boehringer Ingelheim. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
This study's enrollment of 337 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Meloxicam 7.5 mg · Drug: Placebo matching 15 mg meloxicam · Drug: Placebo matching 500 mg mefenamic acid
Drug: Meloxicam 15 mg · Drug: Placebo matching 7.5 mg meloxicam · Drug: Placebo matching 500 mg mefenamic acid
500 mg three times daily
Drug: Mefenamic acid 500 mg · Drug: Placebo matching 7.5 mg meloxicam · Drug: Placebo matching 15 mg meloxicam
Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS)
Time frame: Baseline and day 3-5 of each treatment cycle
Final global assessment of efficacy by patient on a 4-point scale
Time frame: day 3-5 of the second treatment cycle
Final global assessment of efficacy by investigator on a 4-point scale
Time frame: day 3-5 of the second treatment cycle
Final global assessment of tolerability by patient on a 4-point scale
Time frame: day 3-5 of the second treatment cycle
Final global assessment of tolerability by investigator on a 4-point scale
Time frame: day 3-5 of the second treatment cycle
Number of Participants with Adverse Events (AE)
Time frame: Up to 4 weeks after last treatment cycle
Incidence of significant laboratory events
Time frame: Up to 4 weeks after last treatment cycle
Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract
Time frame: Up to 4 weeks after last treatment cycle
Number of gastro-intestinal adverse events (GI-AEs)
Time frame: Up to 4 weeks after last treatment cycle
Duration of hospitalization stay due to GI-AEs
Time frame: Up to 4 weeks after last treatment cycle
Number of additional visits at physician due to GI-AEs
Time frame: Up to 4 weeks after last treatment cycle
Duration of hospitalization due to drug related AEs
Time frame: Up to 4 weeks after last treatment cycle
Number of withdrawals due to AEs
Time frame: Up to 4 weeks after last treatment cycle
Intensity of AEs on a 3-point scale
Time frame: Up to 4 weeks after last treatment cycle
Evaluation of labor and/or daily life disability associated with dysmenorrhea on a VAS
Time frame: Baseline and day 3-5 of each treatment cycle
Change in severity of symptomatology associated with dysmenorrhea
Time frame: Baseline and day 3-5 of each treatment cycle
No study locations are listed for this record.
The record gives a start of Jan 1998 and a primary completion of Apr 1999. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam